South America Solid Tumor Testing Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
South America Solid Tumor Testing Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
South America Solid Tumor Testing Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| South America Solid Tumor Testing Total | xxxx | xxxx | xxxx | 7.4% |
| Brazil | xxxx | xxxx | xxxx | 8% |
| Argentina | xxxx | xxxx | xxxx | 8.3% |
| Colombia | xxxx | xxxx | xxxx | 7.2% |
| Peru | xxxx | xxxx | xxxx | 7.6% |
| Chile | xxxx | xxxx | xxxx | 7.7% |
| Rest of South America | xxxx | xxxx | xxxx | 6.5% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Solid Tumor Testing Market
The competitive landscape of the solid tumor testing market is characterized by a wide spectrum of participants competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established electronics manufacturers, specialized solid tumor testing companies, and emerging start-ups aiming to disrupt the market with creative techniques.
In September 2022, Seagen and LAVA Therapeutics declared a strategic collaboration to manufacture and commercialize LAVA-1223, an advanced epidermal expansion factor receptor that can efficiently detect solid tumors. (Source: https://ir.lavatherapeutics.com/news-releases/news-release-details/seagen-and-lava-therapeutics-announce-exclusive-worldwide#:~:text=News%20%26%20Events-,Seagen%20and%20LAVA%20Therapeutics%20Announce%20Exclusive%20Worldwide%20License%20Agreement%20to,for%20EGFR%2DExpressing%20Solid%20Tumors&text=BOTHELL%2C%20Wash.,GLOBE%20NEWSWIRE)%20%2D%2D%20Seagen%20Inc.)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 1225.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.
- According to Cognitive Market Research, the Brazil solid tumor testing market size was valued at USD 524.60 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Solid tumor testing sales flourish in Brazil due to the rising advancement in technology.
- Argentina's solid tumor testing market had a market share of USD 205.92 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. The demand is augmented by Argentina's stringent environmental regulations.
- Colombia's solid tumor testing market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 109.09 million in 2024.
- Peru solid tumor testing market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 100.51 million in 2024.
- Chile solid tumor testing market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 88.25 million in 2024.
- The Rest of Latin America's solid tumor testing market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 197.32 million in 2024.
The solid tumor testing market in Latin America is constantly expanding, owing to the region’s increasing cancer incidence, growing adoption of precision medicine, and improving healthcare infrastructure. These factors are bolstered by advancements in diagnostic technologies, fostering better patient outcomes and treatment efficacy across the region. Moreover, advanced genetic and molecular testing technologies, coupled with personalized treatment approaches, enhance prognosis and therapeutic efficacy in managing melanoma cases. In conclusion, the solid tumor testing market is driven by increasing incidence rates and demand for early detection.
Analyst Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The South America Solid Tumor Testing Market Analysis is witnessing significant growth in the near future.
In 2023, the Genetic Testing segment accounted for a notable share of the South America Solid Tumor Testing Market Analysis.
Frequently Asked Questions
★ Reviews
Rate this report
South America Solid Tumor Testing Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Type | Genetic Testing, Genetic Test Type, Next generation sequencing (NGS), Real-time PCR (RT-PCR), Fluorescent In-Situ Hybridization (FISH), Fragment Analysis, Conventional Testing |
|---|---|
| Application | Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian, Others |
| End-User | Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutions |
| List of Competitors | Abbott Laboratories, Agilent Technologies, Biocare Medical, LLC., F. Hoffmann-La Roche Ltd, Illumina, Inc., MedGenome, Myriad Genetics, QIAGEN NV., Quest Diagnostics, Thermo Fischer Scientific, Inc. |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 Abbott Laboratories
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 Agilent Technologies
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 R&D Investment (Subject to data availability)
- 1.2.2.4 Financials (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 Biocare Medical
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 R&D Investment (Subject to data availability)
- 1.2.3.4 Financials (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 LLC.
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 R&D Investment (Subject to data availability)
- 1.2.4.4 Financials (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 F. Hoffmann-La Roche Ltd
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 R&D Investment (Subject to data availability)
- 1.2.5.4 Financials (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 Illumina
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 R&D Investment (Subject to data availability)
- 1.2.6.4 Financials (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 Inc.
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 R&D Investment (Subject to data availability)
- 1.2.7.4 Financials (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 MedGenome
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 R&D Investment (Subject to data availability)
- 1.2.8.4 Financials (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.9 Myriad Genetics
- 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.9.2 Business Overview
- 1.2.9.3 R&D Investment (Subject to data availability)
- 1.2.9.4 Financials (Subject to data availability)
- 1.2.9.5 Product Types Specification
- 1.2.9.6 Business Strategy
- 1.2.9.7 Recent Developments
- 1.2.9.8 Management Change
- 1.2.9.9 S.W.O.T Analysis
- 1.2.10 QIAGEN NV.
- 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.10.2 Business Overview
- 1.2.10.3 R&D Investment (Subject to data availability)
- 1.2.10.4 Financials (Subject to data availability)
- 1.2.10.5 Product Types Specification
- 1.2.10.6 Business Strategy
- 1.2.10.7 Recent Developments
- 1.2.10.8 Management Change
- 1.2.10.9 S.W.O.T Analysis
- 1.2.11 Quest Diagnostics
- 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.11.2 Business Overview
- 1.2.11.3 R&D Investment (Subject to data availability)
- 1.2.11.4 Financials (Subject to data availability)
- 1.2.11.5 Product Types Specification
- 1.2.11.6 Business Strategy
- 1.2.11.7 Recent Developments
- 1.2.11.8 Management Change
- 1.2.11.9 S.W.O.T Analysis
- 1.2.12 Thermo Fischer Scientific
- 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.12.2 Business Overview
- 1.2.12.3 R&D Investment (Subject to data availability)
- 1.2.12.4 Financials (Subject to data availability)
- 1.2.12.5 Product Types Specification
- 1.2.12.6 Business Strategy
- 1.2.12.7 Recent Developments
- 1.2.12.8 Management Change
- 1.2.12.9 S.W.O.T Analysis
- 1.2.13 Inc.
- 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.13.2 Business Overview
- 1.2.13.3 R&D Investment (Subject to data availability)
- 1.2.13.4 Financials (Subject to data availability)
- 1.2.13.5 Product Types Specification
- 1.2.13.6 Business Strategy
- 1.2.13.7 Recent Developments
- 1.2.13.8 Management Change
- 1.2.13.9 S.W.O.T Analysis
- 1.2.1 Abbott Laboratories
- 1.1 Top Competitors Analysis
Chapter 2. Global Solid Tumor Testing Market Analysis
- 2.1 Global Solid Tumor Testing Market Analysis
- 2.2 Global Solid Tumor Testing Market Analysis by Type
- 2.3 Global Solid Tumor Testing Market Analysis by Application
- 2.4 Global Solid Tumor Testing Market Analysis by End-User
Chapter 3. South America Solid Tumor Testing Market Analysis
- 3.1 South America Solid Tumor Testing Market Analysis
- 3.2 South America Solid Tumor Testing Market Analysis by Country
- 3.3 South America Solid Tumor Testing Market Analysis by Type
- 3.4 South America Solid Tumor Testing Market Analysis by Application
- 3.5 South America Solid Tumor Testing Market Analysis by End-User
- 3.6 South America Solid Tumor Testing Market Analysis by Key Players
Chapter 4. Brazil Solid Tumor Testing Market Analysis
- 4.1 Brazil Solid Tumor Testing Market Analysis
- 4.2 Brazil Solid Tumor Testing Market Analysis by Type
- 4.3 Brazil Solid Tumor Testing Market Analysis by Application
- 4.4 Brazil Solid Tumor Testing Market Analysis by End-User
- 4.5 Brazil Solid Tumor Testing Market Analysis by Key Players
Chapter 5. Argentina Solid Tumor Testing Market Analysis
- 5.1 Argentina Solid Tumor Testing Market Analysis
- 5.2 Argentina Solid Tumor Testing Market Analysis by Type
- 5.3 Argentina Solid Tumor Testing Market Analysis by Application
- 5.4 Argentina Solid Tumor Testing Market Analysis by End-User
- 5.5 Argentina Solid Tumor Testing Market Analysis by Key Players
Chapter 6. Colombia Solid Tumor Testing Market Analysis
- 6.1 Colombia Solid Tumor Testing Market Analysis
- 6.2 Colombia Solid Tumor Testing Market Analysis by Type
- 6.3 Colombia Solid Tumor Testing Market Analysis by Application
- 6.4 Colombia Solid Tumor Testing Market Analysis by End-User
- 6.5 Colombia Solid Tumor Testing Market Analysis by Key Players
Chapter 7. Peru Solid Tumor Testing Market Analysis
- 7.1 Peru Solid Tumor Testing Market Analysis
- 7.2 Peru Solid Tumor Testing Market Analysis by Type
- 7.3 Peru Solid Tumor Testing Market Analysis by Application
- 7.4 Peru Solid Tumor Testing Market Analysis by End-User
- 7.5 Peru Solid Tumor Testing Market Analysis by Key Players
Chapter 8. Chile Solid Tumor Testing Market Analysis
- 8.1 Chile Solid Tumor Testing Market Analysis
- 8.2 Chile Solid Tumor Testing Market Analysis by Type
- 8.3 Chile Solid Tumor Testing Market Analysis by Application
- 8.4 Chile Solid Tumor Testing Market Analysis by End-User
- 8.5 Chile Solid Tumor Testing Market Analysis by Key Players
Chapter 9. Rest of South America Solid Tumor Testing Market Analysis
- 9.1 Rest of South America Solid Tumor Testing Market Analysis
- 9.2 Rest of South America Solid Tumor Testing Market Analysis by Type
- 9.3 Rest of South America Solid Tumor Testing Market Analysis by Application
- 9.4 Rest of South America Solid Tumor Testing Market Analysis by End-User
- 9.5 Rest of South America Solid Tumor Testing Market Analysis by Key Players
Chapter 10. Type Analysis
- 10.1 Genetic Testing
- 10.2 Genetic Test Type
- 10.3 Next generation sequencing (NGS)
- 10.4 Real-time PCR (RT-PCR)
- 10.5 Fluorescent In-Situ Hybridization (FISH)
- 10.6 Fragment Analysis
- 10.7 Conventional Testing
Chapter 11. Application Analysis
- 11.1 Prostate
- 11.2 Breast
- 11.3 Colorectal
- 11.4 Endometrial
- 11.5 Lung
- 11.6 Melanoma
- 11.7 Brain
- 11.8 Thyroid
- 11.9 Liver
- 11.10 Ovarian
- 11.11 Others
Chapter 12. End-User Analysis
- 12.1 Hospitals
- 12.2 Pharmaceutical & Biotechnology Companies
- 12.3 Contract Research Organizations
- 12.4 Academic Research Institutions
Chapter 13. Qualitative Analysis (Subject to Data Availability)
- 13.1 Market Drivers
- 13.2 Market Restraints
- 13.3 Market Trends
- 13.4 Market Opportunity
- 13.5 Technological Road Map (Subject to Data Availability)
- 13.6 Product Life Cycle (Subject to Data Availability)
- 13.7 Customer and Buyer Behavior Analysis
- 13.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 13.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 13.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 13.7.4 Pricing, Affordability & Value Perception Analysis
- 13.7.5 Customer Segmentation & Demand Pattern Analysis
- 13.8 Industrial Chain Analysis (Subject to Data Availability)
- 13.8.1 Industry Chain Analysis
- 13.8.2 Manufacturing Cost Analysis
- 13.8.3 Supply Side Analysis
- 13.8.3.1 Raw Material Analysis
- 13.8.3.2 Raw Material Procurement Analysis
- 13.8.3.3 Raw Material Price Trend Analysis
- 13.9 PESTEL Analysis
- 13.9.1 Environmental Factors
- 13.9.2 Legal Factors
- 13.9.3 Technological Factors
- 13.9.4 Economic Factors
- 13.9.5 Political Factors
- 13.9.6 Social Factors
- 13.10 Porter’s Five Forces Analysis
- 13.10.1 Degree of Competition
- 13.10.2 Threat of Substitutes
- 13.10.3 Threat of New Entrants
- 13.10.4 Bargaining Power of Buyers
- 13.10.5 Bargaining Power of Suppliers
- 13.11 Patent Analysis (Subject to Data Availability)
- 13.12 ESG Analysis
- 13.13 Geopolitical Outlook
- 13.13.1 Global Power Realignment & Strategic Alliances
- 13.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 13.13.3 International Trade Relations & Market Access Environment
- 13.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 13.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 13.13.6 Technology Sovereignty & Digital Geopolitics
- 13.13.7 Strategic Implications for Investment, Growth & Market Entry
- 13.14 AI & Market Transformation
- 13.14.1 Competitive Landscape Disruption & Strategic Shifts
- 13.14.2 AI-Driven Transformation of Industry Value Chain
- 13.14.3 Evolution of Business Models & Revenue Streams
- 13.14.4 AI-Driven Product, Service & Innovation Transformation
- 13.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 14. Research Findings
- 14.1 Key Takeaways
- 14.2 Analyst Point of View
- 14.3 Assumptions and Acronyms
Chapter 15. Research Methodology and Sources
- 15.1 Primary Data Collection
- 15.1.1 Steps for Primary Data Collection
- 15.1.1.1 Identification of KOL
- 15.1.2 Backward Integration
- 15.1.3 Forward Integration
- 15.1.4 How Primary Research Help Us
- 15.1.5 Modes of Primary Research
- 15.1.1 Steps for Primary Data Collection
- 15.2 Secondary Research
- 15.2.1 How Secondary Research Help Us
- 15.2.2 Sources of Secondary Research
- 15.3 Data Validation
- 15.3.1 Data Triangulation
- 15.4 Data Representation
- 15.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the South America Solid Tumor Testing Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Medical Devices and Consumables Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the South America Solid Tumor Testing Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the south america solid tumor testing market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
